Complement System
As one of the most ancient parts of the immune system, present in evolution long before the development of adaptive immunity. It efficiently protects the host from pathogenic microorganisms, contributes to immune complex regulation and represents an important link between the innate and the specific immune system.Complement activation is initiated via three distinct routes: the Classical, the Alternative, and the Lectin pathways which unite to trigger covalent deposition of Complement proteins onto the target surface with the ultimate goal to destroy the target either by lysis or phagocytosis. The Classical pathway requires immunoglobulins IgM and IgG for its activation. The Alternative pathway provides a rapid, antibody-independent route for complement activation. Factor B, a single chain plasma protein, binds to C3b which renders Factor B susceptible to cleavage by Factor D, a serine protease circulating in serum in active form.
The Lectin pathway provides another antibody-independent way to activate the Complement System. This pathway is initiated either by binding of Mannan Binding Lectin (MBL) to mannose or N-acetylglucoseamine or by binding of Ficolins to acetylated carbohydrates on the surface of pathogens. In order to avoid a deleterious damage to surrounding tissue, both soluble and membrane-bound regulators tightly regulate the complement system. C1-inhibitor binds to C1r, C1s and MASP-2 and prevents further cleavage of C4. C4b-binding protein (C4bp) inactivates the classical pathway C3 convertase and the Factors H and I inhibitthe alternative pathway C3 convertase by cleaving C3b in the enzyme complex.
References
1.Mamidi S, et al. Immunobiology. 2017 Jan;222(1):45-54.
2.Gadjeva M,et al. Methods Mol Biol. 2014;1100:1-9.
The Lectin pathway provides another antibody-independent way to activate the Complement System. This pathway is initiated either by binding of Mannan Binding Lectin (MBL) to mannose or N-acetylglucoseamine or by binding of Ficolins to acetylated carbohydrates on the surface of pathogens. In order to avoid a deleterious damage to surrounding tissue, both soluble and membrane-bound regulators tightly regulate the complement system. C1-inhibitor binds to C1r, C1s and MASP-2 and prevents further cleavage of C4. C4b-binding protein (C4bp) inactivates the classical pathway C3 convertase and the Factors H and I inhibitthe alternative pathway C3 convertase by cleaving C3b in the enzyme complex.
References
1.Mamidi S, et al. Immunobiology. 2017 Jan;222(1):45-54.
2.Gadjeva M,et al. Methods Mol Biol. 2014;1100:1-9.
Immunology/Inflammation
Amino Acids and Derivatives(42)
Antiviral(77)
CD110(2)
Cell wall(0)
Complement System(33)
FLAP(9)
Hydroxylase(14)
Interferon Receptor(6)
IRAK(24)
IκB kinase (IKK)(41)
Lipoxygenase(53)
LTR(13)
MyD88(6)
NOS(85)
PD-1/PD-L1(38)
PGE synthase(14)
RLR(4)
ROS(61)
Scavenger Receptor(2)
SphK(3)
STING(27)
TLR(68)
Complement System
-
PMX 53 acetate(219639-75-5 free base)
产品货号 : M37923
cas no: 852629-88-0
PMX-53 is a potent and orally active CD88 (C5aR) antagonist (IC50: 20 nM) and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2). -
Compstatin control peptide acetate
产品货号 : M37918
cas no: 301544-78-5
Compstatin control peptide 是 Compstatin (HY-P1036) 的阴性对照 。Compstatin 是一种有效的补体系统 C3 (complement system C3) 抑制剂。 -
Vesencumab
产品货号 : M36757
cas no: 1205533-60-3
Vesencumab (MNRP-1685A) 是针对 neuropilin-1 (NRP-1) 的 IG1 抗体。Vesencumab 与 NRP-1 结合并阻止 NRP-1 与 VEGFR-2 偶联。Vesencumab 具有抗血管生成和抗肿瘤活性。Vesencumab可用于转移性实体瘤的研究,包括卵巢癌。 -
Ravulizumab
产品货号 : M36750
cas no: 1803171-55-2
Ravulizumab (ALXN1210) 是一种人源化单克隆抗体,它以高亲和力特异性结合人补体蛋白 C5。Ravulizumab 可用于阵发性睡眠性血红蛋白尿症、非典型溶血性尿毒症综合征和重症肌无力的研究。 -
Tesidolumab
产品货号 : M36737
cas no: 1531594-08-7
Tesidolumab (LFG316) 是一种全人IgG1/λ抗c5单克隆抗体,分子量为143 kDa(不含糖基化)。Tesidolumab (LFG316)阻断C5的切割,防止膜攻击复合体的后续形成。